ABOUT US

MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support.

We believe in restoring dignity and freedom to patients. We believe in therapies that are designed to integrate seamlessly into people’s daily routines, offering confidence without compromise.

Our marketed flagship drug Wynzora^® Cream is more than a drug; it’s a lifelong partner in reclaiming the simplicity and ease of every day for people with plaque psoriasis.

Wynzora^® is partnered with leading pharmaceutical companies specialized in dermatology covering more than 40 countries in four continents representing more than 2.6 billion people.

Read more about Wynzora^® Cream drug for treatment of plaque psoriasis in adults here.

Our approach

We apply cross-silo thinking, combining deep knowledge of immunology with a multi-disciplinary approach spanning all fields of science and product development to market access provide an enhanced ability to identify new treatment opportunities that are addressing high unmet clinical need.

Our operational excellence integrates our commercial experience and market access knowledge built from bringing our drug Wynzora^® Cream to the market in the US and Europe as part of our global partnering strategy on Wynzora^®.

We integrate a network of high-performance experts to maximize execution power and allowing us to identify the optimal strategic pathways to broaden our business and build momentum.

With a holistic focus on patient care, we develop PAD Technology™ based OTC skincare products specifically designed to complement medical treatments and provide soothing relief for dry, itchy skin caused by inflammation.

Read more about our OTC skincare pipeline here.